8 min read
Monthly FDA Guidance and Regulatory News Review - July 2026
This July 2026 regulatory update focuses on the FDA finalizing six guidances that addresses antiviral next-generation...
We provide impactful strategies and solutions to meet your outsourcing needs in order to plan and run your next clinical trial, program or regulatory submission project. Our 25 years of experience helping emerging and small to mid-size biotech firms take their products from IND to NDA approval are worth taking a look at. In 2018 alone, our team prepared the regulatory submissions for 12% of the NMEs approved by the FDA. And, many of those programs we supported since the writing of the study protocols and IND.
Whether you have a compound and need to get started on your IND, or need to recruit patients quickly to get your early phase trials running or just need medical writing or biostatistical support for your programs - Veristat can help.
Speak with us at the Outsourcing in Clinical Trials Southeast conference in Durham, NC on March 26-27, 2019! And, did you know, if you are a Director, VP or C-Suite member of a biotech, pharmaceutical or medical device firm, you can register for free.
Schedule a meeting by filling out the form on the right. Find out how we can help you advance your next clinical trial or regulatory submission to successful outcomes. Or, read some of our recent insightful perspectives.
8 min read
Aug 14, 2026 Veristat Blog
This July 2026 regulatory update focuses on the FDA finalizing six guidances that addresses antiviral next-generation...
1 min read
Aug 12, 2026 Veristat Blog
China is rapidly becoming one of the most influential forces in global drug development—but bringing innovative...